We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...

DeepIntent, the health advertising platform, today launched Data HealthChecks, a pioneering on-platform transparency initiative within its Audience Marketplace. This new program gives clients ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

AbbVie continues to be a leader in the global ... its portfolio of product candidates due to the acquisition of Aliada Therapeutics at the end of October 2024 and Cerevel Therapeutics.

It is currently in the process of acquiring Aliada Therapeutics for $1.4 billion, primarily for its Alzheimer’s treatment in the pipeline. Looking forward, we expect both AbbVie and J&J’s ...

Recent Market Developments .October 28, 2024: AbbVie announced its acquisition of Aliada Therapeutics, strengthening its neuroscience portfolio and enhancing its focus on Alzheimer's disease.